View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
September 2021
COVID-19NewsInto practice | Get involved | Blogs | Events | Announcements


Updates to our managing COVID-19 guideline

On 2 September 2021, we added new recommendations to our managing COVID-19 guideline:

We also updated some existing recommendations:

We've also made minor changes to clarify that NHS England updated their interim clinical commissioning policy on remdesivir for patients hospitalised with COVID-19 (PDF) in June 2021 to include eligibility criteria for people who are significantly immunocompromised.

We are continuously updating this guideline to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.


Trainer coach gives flip chart presentation

Draft guideline published on mental wellbeing at work

In collaboration with Public Health England, we’ve published draft recommendations on how to create the right conditions to support mental wellbeing through an environment and culture of participation, equality, safety and fairness in the workplace based on open communication. The draft guideline states all managers should be given the skills to support employees with mental health issues.

Inclisiarn box and syringe

Final draft guidance approves cholesterol-lowering drug inclisiran

We’ve issued final draft guidance recommending inclisiran for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke. It can be used on its own or alongside statins or other cholesterol lowering drugs.

doctor and male patient during an urology consultation

Final draft guidance recommends apalutamide for prostate cancer

We’ve published final draft guidance recommending apalutamide, plus androgen deprivation therapy, for treating prostate cancer in adults. Apalutamide is an androgen receptor inhibitor that works by blocking the effect of testosterone on prostate cancer cells. It is estimated that around 8,000 people with hormone-sensitive or hormone-relapsed prostate cancer will now be eligible for treatment with this drug.

Red swollen knee with juvenile arthritis

New treatment for people with juvenile idiopathic arthritis

We’ve recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people aged 2 years and older. Juvenile idiopathic arthritis is an inflammation of the joints that begins in children under 16 years of age. More than 1,000 people in England will be eligible for treatment.

Catch up on our latest news

Executive MSc in evaluation of health care interventions and outcomes: applications open for November 2021

NICE and the London School of Economics and Political Science are delivering this course in partnership. It focuses on:

  • health economics
  • evaluation of health care interventions and policies
  • principles of health technology assessment.

You’ll learn from world-leading academics, while gaining practical expertise and technical knowledge from experts at NICE.
The course is designed to fit around full-time work. It is structured into 4 2-week teaching blocks spread over 2 years.

Find out more and apply

Into practice

Impact report highlights progress and innovations in CVD prevention

Our latest impact report on preventing cardiovascular disease (CVD)  details progress made by the health and care system in implementing NICE guidance on the topic. It highlights areas of progress, innovation and challenge, including examples from the COVID-19 pandemic.

Read CVD prevention impact report

Get involved

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have a number of vacancies for lay people to join our committees. Topics include stroke and transient ischaemic attack, asthma and B12 vitamin deficiency. Join us and have an active role in producing a guideline or quality standard.

See all our committee vacancies


Aishah Farooq, lay member of the NICE guideline committee

Hearing the voices of young patients

Aishah Farooq sat as a lay member on the committee that developed our babies, children and young people’s experience of healthcare guideline. She tells us why it’s important for everyone to recognise that babies, children, young people and their families have a choice and a voice when accessing healthcare.

Read more of our latest blog posts


Methods and process review webinar: a focus on MedTech

Register for our webinar to find out what proposed changes to our methods and processes of health technology evaluation mean for MedTech developers and the patients who use their products.

  • Thursday 7 October 2021, 11am to 12noon, on Zoom.
Register for our webinar

World Evidence-Based Healthcare (EBHC) Day: the role of evidence in an infodemic

World EBHC Day takes place on Wednesday 20 October 2021. In response to the World Health Organization's call for action on infodemic management, this year's theme is ‘the role of evidence in an infodemic’. 

NICE and 6 other global leaders in evidence-based healthcare will run a series of events throughout the day. 

Find out more about World EBHC Day


Professor Gillian Leng

Professor Gillian Leng to retire from NICE

NICE chief executive, Professor Gillian Leng, has announced she is to retire from NICE. Professor Leng, who has worked at NICE for over 20 years, is departing to pursue new challenges. Details on recruitment of a successor will follow in due course.

NICE and Cochrane sign collaborative agreement to deliver ‘living’ guideline recommendations

We’ve signed a collaborative agreement with Cochrane that will help us to deliver ‘living’ recommendations across our guideline portfolio. The agreement will enable us to better use Cochrane reviews in responding to changes in the evidence. This will allow us to make efficient and effective updates to the recommendations in our guidelines, thereby supporting one of our core strategic objectives to provide living guideline recommendations that are dynamic and rapidly updated.

ME/CFS guideline roundtable discussion announced

We recently paused publication of our updated guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This decision followed issues raised by some professional groups during the pre-publication period. To fully understand the health professionals’ concerns, we are holding a roundtable meeting to discuss the updated guideline and the issues raised on Monday 18 October. NICE has invited relevant professional organisations, plus representatives from interested patient groups, to attend. The discussion will help to inform NICE’s thinking on the next steps for publication of the guideline.


unsubscribe from this list